141 related articles for article (PubMed ID: 36289743)
1. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.
Sindhu KK; Nehlsen AD; Lehrer EJ; Rowley JP; Stock RG; Galsky MD; Buckstein M
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289743
[TBL] [Abstract][Full Text] [Related]
2. Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Sindhu KK; Leiter A; Moshier E; Lin JY; Carroll E; Brooks D; Shimol JB; Eisenberg E; Gallagher EJ; Stock RG; Galsky MD; Buckstein M
Cancer Treat Res Commun; 2020; 25():100216. PubMed ID: 33049542
[TBL] [Abstract][Full Text] [Related]
3. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xu Y; Li H; Fan Y
Front Oncol; 2021; 11():642883. PubMed ID: 33747966
[TBL] [Abstract][Full Text] [Related]
4. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
Ozluk AA; Karateke M; Sanli UA; Karaca B
Melanoma Res; 2023 Oct; 33(5):417-421. PubMed ID: 37276020
[TBL] [Abstract][Full Text] [Related]
6. Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis.
Comito F; Leslie I; Boos L; Furness A; Pickering L; Turajlic S; Larkin J
J Immunother; 2020 Oct; 43(8):250-255. PubMed ID: 32796274
[TBL] [Abstract][Full Text] [Related]
7. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.
Le UT; Passlick B; Schmid S
J Thorac Dis; 2023 Mar; 15(3):1133-1141. PubMed ID: 37065601
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
9. Solid tumours showing oligoprogression to immune checkpoint inhibitors have the potential for abscopal effects.
Ito M; Abe S; Adachi S; Oshima Y; Takeuchi A; Ohashi W; Iwata T; Ogawa T; Ota A; Kubota Y; Okuda T; Suzuki K
Jpn J Radiol; 2024 Apr; 42(4):424-434. PubMed ID: 38093137
[TBL] [Abstract][Full Text] [Related]
10. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series.
Sia TY; Wan V; Finlan M; Zhou QC; Iasonos A; Zivanovic O; Sonoda Y; Chi DS; Long Roche K; Jewell E; Tew WP; O'Cearbhaill RE; Cohen S; Makker V; Liu YL; Friedman CF; Kyi C; Zamarin D; Gardner G
Int J Gynecol Cancer; 2024 Apr; 34(4):594-601. PubMed ID: 38296517
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
12. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
13. Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy.
Chou B; Lee JH; Saetern L; Venkatesulu BP; Welsh JS; Harkenrider MM
Am J Clin Oncol; 2024 Apr; 47(4):155-160. PubMed ID: 38193499
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
15. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
16. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
17. Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer.
Yu X; Chu X; Wu Y; Zhou J; Zhao J; Zhou F; Han C; Su C
Cancer Drug Resist; 2021; 4(3):728-739. PubMed ID: 35582303
[No Abstract] [Full Text] [Related]
18. Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report.
Bonomo P; Lucidi S; Desideri I; Scotti V; Casati M; Palomba A; Ciabatti C; Garlatti P; Massi D; Gallo O; Livi L
Clin Transl Radiat Oncol; 2020 Jul; 23():16-19. PubMed ID: 32368625
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Clin Transl Radiat Oncol; 2024 Mar; 45():100748. PubMed ID: 38433950
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy.
Wray J; Hawamdeh RF; Hasija N; Dagan R; Yeung AR; Lightsey JL; Okunieff P; Daily KC; George TJ; Zlotecki RA; Trevino J; Dang LH
Oncol Lett; 2017 Mar; 13(3):1087-1094. PubMed ID: 28454218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]